Synoptical view

    Truffle investment
    € 17M
    Stock
    Carmat is listed on EURONEXT GROWTH PARIS since 2010
carmat_2018_07_17_nb_0179.jpg

Management team

stephane_piat.jpg

Stéphane Piat

CEO

pascaledarbonneau_e1545031510663.jpg

Pascale d'Arbonneau

CFO

Board of Directors

jean_pierre_garnier.jpg

Jean-Pierre Garnier

President

In summary

Founded in 2008, designer and developer of the world's most advanced total artificial heart project; Carmat's goal is to fill the well-known heart transplant gap for the tens of thousands of people suffering from irreversible terminal heart failure, the most severely affected population among the 20 million patients with this progressive disease in Europe and the United States. Carmat intends to become the number one leader in heart transplantation.

News

News

Positive interim results from the first part of the PIVOT study (10 patients), 70% of patients in this first cohort achieved a six-month survival with the bioprosthesis or a successful total transplant, healthy heart within 6 months of implantation of the device.

0_banner_home_tetris_1_.png

Next start-up

CoolGames